Proceedings from the BMT CTN Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Holstein SA., Asimakopoulos F., Azab AK., Bianchi G., Bhutani M., Crews LA., Cupedo T., Giles H., Gooding S., Hillengass J., John L., Kaiser S., Lee L., Maclachlan K., Pasquini MC., Pichiorri F., Shah N., Shokeen M., Shy BR., Smith EL., Verona R., Usmani SZ., McCarthy PL.
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on January 7, 2022. This workshop included presentations by basic, translational and clinical researchers with expertise in plasma cell dyscrasias. Four main topics were discussed: 1) platforms for myeloma disease evaluation; 2) insights into pathophysiology; 3) therapeutic target and resistance mechanisms; and 4) cellular therapy for multiple myeloma. In the present report, we provide a comprehensive summary of these workshop presentations.